Author Interviews, Herpes Viruses, Science, University of Pennsylvania, Vaccine Studies / 23.09.2019
Penn Researchers Developing Vaccine To Prevent Genital Herpes Infection
MedicalResearch.com Interview with:
[caption id="attachment_51550" align="alignleft" width="148"]
Prof. Friedman[/caption]
Harvey M. Friedman, MD
Professor of Medicine/Infectious Diseases
University of Pennsylvania
Philadelphia, PA 19104-6073
MedicalResearch.com: What is the background for this study?
Response: Mice and guinea pigs are the animal models used to evaluate candidate vaccines for preventing genital herpes. My lab has been working on such a vaccine.
Our candidate vaccine contains 3 immunogens. One immunogen is a protein on the virus that is required for the virus to enter cells (viruses need to enter cells to replicate). The other two immunogens are proteins on the virus that help the virus escape immune attack.
Our intent is to produce antibodies to these 3 proteins by immunization and that the antibodies will bind to the proteins on the virus and block the protein functions. The virus then will not be able to enter cells and will not be able to use its evasion strategies to avoid the immune responses generated by the vaccine. Our vaccine aimed at preventing immune evasion is novel as a component of a genital herpes vaccine.
Prof. Friedman[/caption]
Harvey M. Friedman, MD
Professor of Medicine/Infectious Diseases
University of Pennsylvania
Philadelphia, PA 19104-6073
MedicalResearch.com: What is the background for this study?
Response: Mice and guinea pigs are the animal models used to evaluate candidate vaccines for preventing genital herpes. My lab has been working on such a vaccine.
Our candidate vaccine contains 3 immunogens. One immunogen is a protein on the virus that is required for the virus to enter cells (viruses need to enter cells to replicate). The other two immunogens are proteins on the virus that help the virus escape immune attack.
Our intent is to produce antibodies to these 3 proteins by immunization and that the antibodies will bind to the proteins on the virus and block the protein functions. The virus then will not be able to enter cells and will not be able to use its evasion strategies to avoid the immune responses generated by the vaccine. Our vaccine aimed at preventing immune evasion is novel as a component of a genital herpes vaccine.
Dr. Hongying (Daisy) Dai[/caption]
Hongying (Daisy) Dai, PhD
Associate Professor
Department of Biostatistics | College of Public Health
University of Nebraska Medical Center
Omaha
MedicalResearch.com: What is the background for this study?
Response: Previous studies have reported a surge in e-cigarette use among youth during the 2017 - 2018. For instance, the prevalence of current (past 30-day) e-cigarette use increased by 77.8% (from 11.7% to 20.8%) among high school students and by 48.5% (from 3.3% to 4.9%) among middle school students.
As a result, the Food and Drug Administration (FDA) warns that youth e-cigarette use is reaching an epidemic proportion in September 2018. Whether e-cigarette use prevalence also increased among young adults (aged 18-24 years), a population with high e-cigarette use rates and vulnerability to nicotine dependence, is unknown.






